title: Phase II study with ifosfamide, carboplatin, etoposide (ICE regimen) at intermediate dosage for advanced non small cell lung cancer (NSCLC).
abstract: We have evaluated the combination of ifosfamide, carboplatin and etoposide (ICE regimen) along with mesna in 26 previously untreated patients with non small cell lung cancer (NSCLC). Thirteen stage III B and 13 stage IV patients received intermediate doses of ifosfamide (1000 mg/m2), carboplatin (120 mg/m2) and etoposide (120 mg/m2) given intravenously on day 1 to 3 every 4 weeks. Except for one patient who experienced grade 3 transient thrombocytopenia no major events of hematological or systemic toxicity were observed. Response rate (27%, 95% C.I., 10 to 44%), median duration of response (9 months, range 6-15), and survival (9.5 months, range 2-44+) were comparable to those achieved with conventional cisplatin-containing regimens. Our ICE combination, as compared to standard or high dose schedules appears effective, safe, well tolerated, and devoid of severe hematological toxicity.
authors.affiliation: Divisione di Oncologia Medica, IRCCS Fondazione Salvatore Maugeri, Clinica del Lavoro e della Riabilitazione, Pavia, Italy.
authors.forename: P
authors.initials: P
authors.lastname: Preti
authors.forename: G
authors.initials: G
authors.lastname: Poggi
authors.forename: A M
authors.initials: AM
authors.lastname: Cuomo
authors.forename: F S
authors.initials: FS
authors.lastname: Robustelli della Cuna
authors.forename: A
authors.initials: A
authors.lastname: Zambelli
authors.forename: L
authors.initials: L
authors.lastname: Pavesi
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000473:pathology; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D015080:Mesna / Q000008:administration & dosage; D008875:Middle Aged; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D005047:Etoposide; D016190:Carboplatin; D015080:Mesna; D007069:Ifosfamide